These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3602473)

  • 1. Reversal by cholecystokinin of apomorphine-induced inhibition of dopamine release in the nucleus accumbens of the rat.
    Blaha CD; Phillips AG; Lane RF
    Regul Pept; 1987 Jun; 17(6):301-10. PubMed ID: 3602473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens.
    Lane RF; Blaha CD; Phillips AG
    Brain Res; 1986 Nov; 397(1):200-4. PubMed ID: 3801862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin-induced inhibition of dopamine neurotransmission: comparison with chronic haloperidol treatment.
    Lane RF; Blaha CD; Phillips AG
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(2-3):291-9. PubMed ID: 2819952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of cholecystokinin on the in vivo release of newly synthesized [3H]dopamine from the nucleus accumbens of the rat.
    Voigt MM; Wang RY; Westfall TC
    J Neurosci; 1985 Oct; 5(10):2744-9. PubMed ID: 4045551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholecystokinin facilitates ejaculation in male rats: blockade with proglumide and apomorphine.
    Pfaus JG; Phillips AG
    Eur J Pharmacol; 1987 Sep; 141(3):331-8. PubMed ID: 3666030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine does not reverse reduced basal dopamine release in rat striatum and nucleus accumbens after chronic haloperidol treatment.
    Ichikawa J; Meltzer HY
    Brain Res; 1990 Jan; 507(1):138-42. PubMed ID: 2302571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic haloperidol decreases dopamine release in striatum and nucleus accumbens in vivo: depolarization block as a possible mechanism of action.
    Lane RF; Blaha CD
    Brain Res Bull; 1987 Jan; 18(1):135-8. PubMed ID: 3828839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological studies on the specificity of the cholecystokinin antagonist proglumide.
    Chiodo LA; Freeman AS; Bunney BS
    Brain Res; 1987 May; 410(2):205-11. PubMed ID: 3036308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of cholecystokinin (CCK-8) on dopamine-containing nerve terminals in the caudate nucleus and nucleus accumbens of the anesthetized rat: an in vivo electrochemical study.
    Gerhardt GA; Friedemann M; Brodie MS; Vickroy TW; Gratton AP; Hoffer BJ; Rose GM
    Brain Res; 1989 Oct; 499(1):157-63. PubMed ID: 2804664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balance of glutamate and dopamine in the nucleus accumbens modulates self-stimulation behavior after injection of cholecystokinin and neurotensin in the rat brain.
    Heidbreder C; Gewiss M; De Mot B; Mertens I; De Witte P
    Peptides; 1992; 13(3):441-9. PubMed ID: 1523160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat.
    Debonnel G; Gaudreau P; Quirion R; de Montigny C
    J Neurosci; 1990 Feb; 10(2):469-78. PubMed ID: 2137531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine release in the nucleus accumbens of freely moving rats determined by on-line dialysis: effects of apomorphine and the neuroleptic-like peptide desenkephalin-gamma-endorphin.
    Radhakishun FS; Westerink BH; van Ree JM
    Neurosci Lett; 1988 Jul; 89(3):328-34. PubMed ID: 2901702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol.
    Imperato A; Di Chiara G
    J Pharmacol Exp Ther; 1986 Oct; 239(1):219-28. PubMed ID: 3761194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin.
    Voigt MM; Wang RY
    Brain Res; 1984 Mar; 296(1):189-93. PubMed ID: 6324955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence.
    Crawley JN; Stivers JA; Blumstein LK; Paul SM
    J Neurosci; 1985 Aug; 5(8):1972-83. PubMed ID: 4040554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiological effects of cholecystokinin: central dopaminergic systems.
    Wang RY; White FJ
    Prog Clin Biol Res; 1985; 192():95-103. PubMed ID: 4080721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecystokinin antagonist lorglumide reverses chronic haloperidol-induced effects on dopamine neurons.
    Jiang LH; Kasser RJ; Wang RY
    Brain Res; 1988 Nov; 473(1):165-8. PubMed ID: 3208120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular dopamine in the anterior nucleus accumbens is distinctly affected by ventral tegmental area administration of cholecystokinin and apomorphine: data from in vivo voltammetry.
    Reum T; Fink H; Marsden CA; Morgenstern R
    Neuropeptides; 1998 Apr; 32(2):161-6. PubMed ID: 9639255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does cholecystokinin potentiate dopamine action in the nucleus accumbens?
    Wang RY; Hu XT
    Brain Res; 1986 Aug; 380(2):363-7. PubMed ID: 3756487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neuroleptic-like peptide desenkephalin-gamma-endorphin does not antagonize the dopamine receptor agonist-induced inhibition of the release of [3H]dopamine from rat nucleus accumbens slices in vitro.
    Radhakishun FS; Stoof JC; Mulder AH; Versteeg DH; van Ree JM
    Brain Res; 1987 Nov; 426(2):235-42. PubMed ID: 2961411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.